Archive for the ‘immunology retractions’ Category
We’ve been reporting on retractions of research published by Cardiff University scientists following an investigation into their work. On Monday, we noted a new retraction of work by the group in Cancer Research, which we thought was the second retraction following one in the Journal of Immunology in 2011. But it turns out there was another retraction published at the same time in the same journal, which we now know about thanks to commenter David Hardman and PubPeer.
In April, a Cardiff investigation found that Rossen Donev, a former researcher at the university, had manipulated images in four different papers. Donev, who was at the University of Swansea until August, according to his LinkedIn profile, and is now director of Biomed Consult Ltd., had already retracted a Journal of Immunology paper in late 2011 after a different Cardiff investigation.
The investigation cleared co-author and dean Paul Morgan of misconduct. Morgan resigned from Cardiff in August, but “he categorically denied that his decision had anything to do with the misconduct investigation,” according to Times Higher Education.
About a month ago, we reported on a retraction by Pamela Ronald, of the University of California, Davis, and colleagues. We noted then that this was a case of scientists doing the right thing. Ronald contacted us after that post ran, and let us know that there would be another retraction shortly. That retraction notice has now appeared, in Science: Read the rest of this entry »
Holy Chutzpah, Batman! A team of researchers in India has retracted their 2012 paper in PLoS One on botulinum toxin for plagiarism — while blaming the journal for failing to use its “soft wares” to catch the plagiarism.
The article, “Small-Molecule Quinolinol Inhibitor Identified Provides Protection against BoNT/A in Mice,” was written by a group from the Defence Research and Development Establishment, in Madhya Pradesh.
A group of animal health researchers from the Chinese Academy of Agricultural Sciences have lost their 2009 paper in the Journal of Microbiology and Biotechnology because they’d published the data in at least four other articles.
The article was titled “Human Regulatory T Cells Require IL-35 To Mediate Suppression and Infectious Tolerance.” (On Pubmed the title has the rather ironic precursor “Cutting edge” in front). Here’s the abstract: Read the rest of this entry »
University of Glasgow professor Foo Yew “Eddy” Liew, a Fellow of the Royal Society, has retracted a paper in Cellular Immunology because it duplicated one of his earlier papers in the Proceedings of the National Academy of Sciences (PNAS).
We’ve often found that when some authors refuse to sign retraction notices, there’s a much bigger story than terse notices let on. And a retraction in this week’s Nature of a 19-year-old paper is a shining example of that.
Here’s the brief notice for “Oligosaccharide ligands for NKR-P1 protein activate NK cells and cytotoxicity,” a 1994 paper by researchers from the UK and the Czech Republic that had already been subject to a 1996 correction: Read the rest of this entry »
Why I retracted my Nature paper: A guest post from David Vaux about correcting the scientific record
Last month, Ivan met David Vaux at the 3rd World Conference on Research Integrity in Montreal. David mentioned a retraction he published in Nature, and we thought it would be a great guest post on what it’s like to retract one of your own papers in an attempt to clean up the literature.
In September 1995 Nature asked me to review a manuscript by Bellgrau and co-workers, which subsequently appeared. I was very excited by this paper, as it showed that expression of CD95L on Sertoli cells in allogeneic mismatched testes tissue transplanted under the kidney capsule was able to induce apoptosis of invading cytotoxic T cells, thereby preventing rejection. As I wrote in a News and Views piece, the implications of these findings were enormous – grafts engineered to express CD95L would be able to prevent rejection without generalized immunosuppression.
In fact, I was so taken by these findings that we started generation of transgenic mice that expressed CD95L on their islet beta cells to see if it would allow islet cell grafts to avoid rejection and provide a cure for diabetes in mismatched recipients.
Little did we know that instead of providing an answer to transplant rejection, these experiments would teach us a great deal about editorial practices and the difficulty of correcting errors once they appear in the literature. Read the rest of this entry »